Clinical Trials - August 12, 2021
Further positive trial results from Ultimovacs
Ultimovacs has announced positive results from the second cohort of 10 patients after one year of its ongoing US-based Phase I clinical trial. The clinical trial evaluates the company’s universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab as a first-line treatment in metastatic malignant melanoma. “These latest results are compelling, and in […]
Uncategorized - August 11, 2021
Genetic Analysis co-develops HumGut
Norwegian molecular diagnostics specialist, Genetic Analysis has announced that the first publication from the HumGut microbiome database has appeared in the journal Microbiome. HumGut comprises a collection of about 30,000 genomes, covering the broad diversity of bacterial genomes found in the human gut. Unique to HumGut is that the genome collection has been filtered towards […]
Clinical Trials - May 24, 2021
New promising findings about Ultimovacs’ cancer vaccine
Ultimovacs has announced that its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor pembrolizumab, demonstrated a 60% objective response rate (ORR) in metastatic malignant melanoma. All patients have been observed for at least 18 months and median observation time is 21 months. “Further strengthen the foundation for our broad Phase II clinical program […]
Uncategorized - May 11, 2021
A glimpse of hope in tackling antibiotic resistance
Start-up company AdjuTec’s novel antibiotic resistance breakers may help to facilitate reduced use of antibiotics. If there is one positive thing about the COVID-19 pandemic, it could perhaps be our increased awareness of infectious diseases. “The COVID-19 pandemic has been a mind-opener to society’s vulnerability for infectious diseases in general. This includes the importance of […]
Business article - March 17, 2021
OCC Incubator relaunches start-up program
Oslo Cancer Cluster (OCC) Incubator relaunches the programme for start-ups in cancer innovation under the new name OCC Accelerator. OCC Accelerator will identify, select, and develop promising innovations that will improve the lives of cancer patients, reports Sofia Lindén, Oslo Cancer Cluster. The aim is to make the projects attractive for private and public investments. […]
Collaboration - December 21, 2020
Norwegian public-private agreement for precision cancer medicine
The new initiative CONNECT aims to ensure that precision medicine reaches the patients. The new initiative, called CONNECT (Norwegian Precision Cancer Medicine Implementation Consortium), is a direct response to Health Minister Bent Høie’s political guidance to accelerate the implementation of precision medicine for Norwegian patients. It also responds to the Health Minister’s ambition to increase […]
